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Summary Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and
dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary
results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
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Primary amyloidosis occurs when amyloidogenic monoclonal
light chains precipitate, forming protein complexes that cause
organ dysfunction. The abnormal light chain is secreted by an
aberrant monoclonal B-cell population that has relatively low
proliferative activity (Gertz et al, 1989; Perfetti et al, 1994).
The disease incidence is low and treatment remains contro-
versial, the alkylating agent melphalan being the mainstay oftreat-
ment. Response rates to melphalan-based therapy, in all cases of
amyloidosis, are typically 18-28% with a median survival of 18
months overall, and 50 months in those with objective response
(Kyle and Greipp, 1983; Kyle et al, 1985, 1997).
Patients with nephrotic syndrome, normal serum creatinine and
no cardiac involvement may represent a better prognostic group
with higher response rates (30-39%) and longer median survival
(Kyle and Greipp, 1983; Kyle et al, 1985; Marione et al, 1994;
Merlini et al, 1995; Skinner et al, 1996). Patients whose disease
responds to treatment have a 5-year survival of 50-78%, although
the median survival of the whole population is 12-28 months
(Kyle and Greipp, 1983; Kyle et al, 1985, 1997; Fielder and Durie,
1986; Skinner et al, 1996).
Combination chemotherapy for AL amyloidosis has been used
less widely, mainly because of poor performance status and
perceived unsuitability of patients for such treatments, and it is
often used after melphalan resistance has occurred (Case et al,
1977; Fielder and Durie, 1986; Levy et al, 1988). As vincristine,
doxorubicin and dexamethasone (VAD) chemotherapy is consider-
ably more effective when used at presentation of multiple
myeloma than as salvage (Anderson et al, 1995), we were
prompted to evaluate this regimen for first-line therapy in primary
light chain amyloid (AL).
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METHODS
We retrospectively analysed the outcome ofpatients with a biopsy-
proven diagnosis ofAL (11 patients) and nephrotic syndrome (NS)
referred to the Christie Hospital between 1985 and 1996, and
present the results as a preliminary descriptive study. Nephrotic
syndrome was defined as 24-h urinary total protein (UTP) > 3 g,
hypoalbuminaemia (< 30 g 1-') and oedema. Ten patients were
diagnosed by renal biopsy following presentation with NS and
were previously untreated. One patient was diagnosed by subcuta-
neous fat aspiration following the development of NS 3 years after
initial presentation with myeloma and vertebral AL that had been
treated with melphalan and prednisolone (MP). Amyloid was
diagnosed with Congo red stain and classified using immunohisto-
chemistry (Linke et al, 1986). Monoclonal paraprotein was
confirmed by serum/urine immunoelectrophoresis.
We analysed the patients according to primary treatment
received: four patients were treated with a 4-day infusion of
vincristine (1.6 mg) and doxorubicin (36 mg m 2) together with
dexamethasone (40 mg day-' for 4 days) (VAD) that was repeated
every 3 weeks and followed by consolidation treatment every
6 weeks with melphalan (10mg day-' for 5 days) and
prednisolone (50 mg day-' for 5 days) (MP) for I year and then
maintenance ux,h-interferon. Seven patients received 6-weekly MP
alone for 1-47 cycles (median ten).
Comparison is also made with patients with renal biopsy-proven
AL and NS from the North Western Glomerular Registry 1985-94
and Royal Sussex County Hospital 1985-96, treated with best
supportive care, including dialysis.
A partial response (PR) was defined as a reduction in UTP to
< 3 g without progression of renal failure, the return of serum
albumin to the normal range (> 30 g 1-'), together with a complete
resolution of serum/urine monoclonal protein.
RESULTS
The two treatment groups and supportive care controls
appear similar with respect to age, mean arterial blood pressure,
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Table 1 Patient characteristics
Patient characteristics
Treatment
Age
Sex
Karnofsky
performance (%)
Pretreatment characteristics
Haemoglobin (g dl-')
Paraprotein type
BM (%)
Lytic lesions
Myeloma
Cardiac failure
Other organ
involvement with AL
deposition
Pretreatment renal evaluation
Creatinine (imol 1-')
Creatinine clearance
(ml min-')
Proteinuria
(g 24 h-1)
Albumin (g 1-')
VAD
57
F
80
12.7
XLC
20
No
Yes
No
VAD
46
M
40
13.9
KLC
14
No
Yes
No
Rectum,
liver,
spleen,
bone
marrow
VAD VAD MP
65 66 82
M M M
50 60 90
13.3
XLC
4
No
No
Yes
Liver,
stomach
14.4
IgGX
13
No
Yes
No
Liver
13.3
IgGk
1
Yes
Yes
No
Bone,
skin
MP
62
M
90
14.7
kLC
9
No
No
No
Skin,
stomach
MP
64
F
90
14.6
IgGk
4
No
No
No
MP
62
F
80
14.6
XLC
0
No
No
No
MP
71
F
80
15.1
IgAK
5
No
No
No
MP
58
F
50
11.4
IgGX
5
Yes
Yes
Yes
Liver
MP
69
M
70
11.4
IgGX
6
No
No
No
90 157 110 87 109 151 80 110 68 117 194
94 26 95 94 117 105 121 39 116 23 39
7.1 42.4 10.2 3.4 4.1 20 13.54 5.6 5.76 13.25 7.3
30 20 17 23 26 18 20 28 21 12 29
LC, light chain; Ig, immunoglobulin.
proteinuria, serum albumin, glomerular filtration rate and blood
counts. The disease burden/organ dysfunction in the MP and VAD
groups appears similar (Table 1) with good preservation of bone
marrow (median haemoglobin 13.9 vs 13.6 g dl-1) and renal func-
tion (median serum creatinine 113 vs 100 .tmol 1-1) and degree of
nephrotic syndrome (median UTP 7.25 vs 8.6 g and serum
albumin 23 vs 21 g 1-') respectively. One patient in each of the
VAD and MP groups had symptomatic cardiac failure with cardiac
amyloid infiltration confirmed at post mortem. The remaining
patients had no electrocardiographic, echocardiographic or isotope
evidence ofimpaired cardiac function.
The interval between diagnosis and treatment was 6-65
(median 6) and 40-497 (median 138) days for the VAD- and MP-
treated group respectively. The VAD group had a lower perfor-
mance status and was deemed to require immediate treatment.
The response rates and survival characteristics are shown in Table
2. Three out of four patients achieved PR with VAD and are alive
and in remission 4.1, 6.5 and 9.3 years (median survival of group
64.5 months) from diagnosis, whereas those treated with
supportive care survived for a median of 11.7 months with no
spontaneous responses. Two of seven patients treated with MP
alone achieved PR, of whom only one is alive and in continuing
PR at 3.6 years; the second died ofrefractory anaemia with excess
of blasts in transformation (RAEBt) after 7.1 years. The median
survival in this group was 17.7 months. One patient in each treat-
ment group died of gastrointestinal haemorrhage related to
autopsy-proven gastric amyloid. When VAD was commenced
after failure of MP in two patients no response was achieved,
although one patient remains alive at 13 months having received
three cycles of VAD, the other died of gastrointestinal haemor-
rhage after three cycles of VAD.
In this group of patients with amyloid treated with VAD, the
toxicity was similar to that seen when patients with myeloma are
treated with VAD.
Treatment of patients with poor prognostic features can be
successful: a 49-year-old man with a performance status of 40%
(Karnofsky et al, 1948) was admitted with a UTP of 42.4g,
a serum albumin of 20 g 1-' and a creatinine clearance of
23 ml min-'. A bone marrow aspirate revealed 14% plasma cells
and AL was confirmed on renal, rectal and bone marrow biopsies.
['23I]SAP (serum amybid p component) scintigraphy confirmed
heavy amyloid deposition in liver, spleen, kidneys and bone
marrow (Hawkins et al, 1988). The patient was treated with six
cycles of VAD, followed by 6-weekly oral melphalan and pred-
nisolone (MP) and subsequently ox2b-interferon. Improvement was
rapid with a50% reduction in serum monoclonal protein concentra-
tion and urinary total protein after six cycles ofVAD and only three
of melphalan and prednisolone (322 days). Partial response was
achieved after 3.9 years. The patient remains in continuing PR with
a good performance status and adaily UTP < 3 g 4 years later and a
recent SAP scan showed only minor abnormalities ofkidneys, liver
and spleen with continuing improvement since commencing inter-
feron. The other two VAD responders had a reduction in UTP from
7.1 and 3.4 to < 0.05 g. The latter also had hepatic involvement,
which resolved completely (disappearance of hepatomegaly and
normalization ofderanged liver function tests).
DISCUSSION
These preliminary data support the further investigation ofVAD as
the initial treatment regimen for AL. Treatment was not allocated
by randomization and there are clearly differences between the
two groups. For example, more patients fulfilled the diagnostic
criteria for myeloma (Salmon and Cassady, 1993) in the VAD-
treated group. The presence or absence of myeloma is not,
however, a prognostic factor for survival in the first year after
diagnosis (Kyle and Gertz, 1995). Both sets ofpatients had similar
median age, performance status, proteinuria, hypoalbuminaemia
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Table 2 Response rates and survival characteristics
VAD MP Best supportive
care
Partial response rate 3 of 4 2 of 7 0 of 18
Median time to partial response (days) 357 659
(absence of M-protein and UTP < 3 g)
Median survival from diagnosis (days) 1935 530 395
Median survival from treatment (days) 1932 392
and renal impairment. Cardiac amyloid is a poor prognostic factor
(Gertz et al, 1991; Kyle and Gertz, 1995; Skinner et al, 1996) and
there was one patient in each treatment group. The PR rate in three
of four VAD-treated patients is interesting and includes the most
severely affected patient. The response rate in those receiving MP
(two of seven) was similar to the response rates in published series
from randomized trials (Kyle and Greipp, 1983; Kyle et al, 1985,
1997; Marione et al, 1994; Merlini et al, 1995). The fact that VAD
was followed by MP makes interpretation difficult. The time to
response was shorter in those treated with VAD than MP alone
(median 357 and 659 days to PR respectively) and all three
exhibited evidence of response before commencement of MP. The
survival of VAD-treated patients is better than that of melphalan-
treated patients and control subjects treated with supportive care.
We believe that this report will be of interest to clinicians who
treat AL. We have shown that VAD can be used in patients ofpoor
performance and it may have an advantage in patients with
moderate to severe renal impairment, as the drugs are not renally
excreted. Aggressive myeloablative therapy with high-dose
melphalan has recently been shown to be possible in some
patients (Comenzo et al, 1996). Patients with NS caused by AL
should be considered for chemotherapy. Prospective randomized
trials are required to assess the benefits of newer regimens,
such as VAD, over conventional treatment with melphalan and
prednisolone.
ABBREVIATIONS
AL, primary (light-chain) amyloid; MP, melphalan and pred-
nisolone; NS, nephrotic syndrome; PR, partial response; SAP,
serum amyloid P component; UTP; 24-h urinary total protein;
VAD, vincristine, doxorubicin and dexamethasone combination
chemotherapy.
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